CAMK2A Gene

CAMK2A — Calcium/Calmodulin-Dependent Protein Kinase II Alpha

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CAMK2A Gene</th>
</tr>
<tr>
<td class="label">Process</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[LTP](/mechanisms/long-term-potentiation) induction</td>
<td>CaMKII autophosphorylation at T286</td>
</tr>
<tr>
<td class="label">LTD induction</td>
<td>Protein phosphatases reverse CaMKII action</td>
</tr>
<tr>
<td class="label">[LTP](/mechanisms/long-term-potentiation) maintenance</td>
<td>Persistent CaMKII activity</td>
</tr>
<tr>
<td class="label">Memory consolidation</td>
<td>CREB activation, gene transcription</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">CaMKII inhibitors</td>
<td>KN-62, AIP</td>
</tr>
<tr>
<td class="label">CaMKII activators</td>
<td>Peptide fragments</td>
</tr>
<tr>
<td class="label">BDNF analogs</td>
<td>BDNF, NT-3</td>
</tr>
<tr>
<td class="label">PDE inhibitors</td>
<td>Ibudilast</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-CAMK2A</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">p-CaMKII (T286)</td>
<td>Brain tissue, CSF</td>
</tr>
<tr>
<td class="label">CaMKII activity</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">p-NR2B (S1303)</td>
<td>Brain tissue</td>
</tr>
<

...

CAMK2A — Calcium/Calmodulin-Dependent Protein Kinase II Alpha

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CAMK2A Gene</th>
</tr>
<tr>
<td class="label">Process</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">[LTP](/mechanisms/long-term-potentiation) induction</td>
<td>CaMKII autophosphorylation at T286</td>
</tr>
<tr>
<td class="label">LTD induction</td>
<td>Protein phosphatases reverse CaMKII action</td>
</tr>
<tr>
<td class="label">[LTP](/mechanisms/long-term-potentiation) maintenance</td>
<td>Persistent CaMKII activity</td>
</tr>
<tr>
<td class="label">Memory consolidation</td>
<td>CREB activation, gene transcription</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">CaMKII inhibitors</td>
<td>KN-62, AIP</td>
</tr>
<tr>
<td class="label">CaMKII activators</td>
<td>Peptide fragments</td>
</tr>
<tr>
<td class="label">BDNF analogs</td>
<td>BDNF, NT-3</td>
</tr>
<tr>
<td class="label">PDE inhibitors</td>
<td>Ibudilast</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-CAMK2A</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">p-CaMKII (T286)</td>
<td>Brain tissue, CSF</td>
</tr>
<tr>
<td class="label">CaMKII activity</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">p-NR2B (S1303)</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">PARKINSON</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">47 edges</a></td>
</tr>
</table>

Introduction

Camk2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The CAMK2A gene encodes the alpha subunit of Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII), one of the most abundant proteins in the brain, constituting up to 2% of total brain protein. CaMKII is a serine/threonine protein kinase that functions as a molecular decoder of calcium signals, playing essential roles in synaptic plasticity, learning, and memory. The CAMK2A isoform is predominantly expressed in excitatory [neurons](/entities/neurons) of the forebrain, particularly in the hippocampus and cerebral cortex. Dysregulation of CaMKII signaling is implicated in Alzheimer's disease, Parkinson's disease, epilepsy, intellectual disability, and various other neurological disorders.

Gene Structure

• Gene length: ~95 kb
• Exons: 13 coding exons
• Promoter: Activity-dependent, regulated by CREB
• Alternative splicing: Generates multiple isoforms

Isoforms

• CaMKIIα: Brain-specific, 12 subunits
• CaMKIIβ: Brain and muscle, regulates localization
• CaMKIIγ/δ: Ubiquitous expression

Protein Structure

CaMKII forms a holoenzyme with 12 subunits arranged in two stacked hexameric rings:

Subunit Structure

• N-terminal catalytic domain: Kinase activity
• Regulatory domain: Autoinhibitory, calmodulin-binding
• Association domain: Multimerization
• C-terminal variable region: Targeting elements

Key Features

• T286 autophosphorylation: Calcium-independent activity
• T305/T306: Inhibition of calmodulin binding
• F506: F-site for calmodulin trapping

Normal Function

Synaptic Plasticity

Molecular Mechanisms

Calcium influx: [NMDA](/entities/nmda-receptor) receptors, voltage-gated calcium channels

Calmodulin binding: Calcium-calmodulin activates CaMKII

Autophosphorylation: T286 becomes phosphorylated

Calcium-independent activity: Truncated CaMKII remains active

Substrate phosphorylation: NR2B, AMPA receptors, CREB

Synaptic targeting: PSD-95, NMDA receptor complexes

Brain Region Distribution

• Hippocampus: Highest expression in CA1 and CA3 pyramidal neurons
• Cerebral cortex: Layers II-III and V pyramidal neurons
• Striatum: Medium spiny neurons
• Amygdala: Principal neurons
• Thalamus: Relay neurons

Cell Type Specificity

• Excitatory glutamatergic neurons: Very high
• Inhibitory GABAergic neurons: Low
• [Astrocytes](/entities/astrocytes): Minimal
• Oligodendrocytes: Minimal

Role in Neurodegeneration

Alzheimer's Disease

CaMKII signaling is significantly impaired in Alzheimer's disease at multiple levels:

• Reduced CaMKII activity: Postmortem AD brain shows 40-60% reduction
• [Tau](/proteins/tau) hyperphosphorylation: CaMKII can phosphorylate [tau](/proteins/tau) at multiple sites (Ser262, Thr231)
• Synaptic dysfunction: Impaired LTP correlates with memory deficits
• [Aβ](/proteins/amyloid-beta) toxicity: Aβ oligomers disrupt CaMKII localization
• NMDA receptor dysregulation: Altered NR2B phosphorylation

Therapeutic strategies:

• CaMKII activators (experimental)
• BDNF to restore CaMKII signaling
• PDE inhibitors to enhance cAMP/CaMKII pathway

Parkinson's Disease

• Dopaminergic signaling: CaMKII modulates D1/D2 receptor signaling
• L-DOPA-induced dyskinesia: CaMKII hyperactivity in striatum
• [α-synuclein](/proteins/alpha-synuclein) toxicity: CaMKII may phosphorylate α-syn
• Neuroprotection: CaMKII activation provides dopaminergic protection

Epilepsy

• Gain-of-function mutations: Cause early-onset epileptic encephalopathy
• Seizure-induced activation: CaMKII upregulation after seizures
• Synaptic hyperexcitability: Enhanced glutamate release
• Therapeutic targeting: CaMKII inhibitors in development

Intellectual Disability and Autism

• De novo mutations: Associated with ID and ASD
• Synaptic dysfunction: Impaired activity-dependent plasticity
• Cognitive deficits: Memory and learning impairments

Stroke and Traumatic Brain Injury

• Ischemic injury: CaMKII activation during ischemia
• Excitotoxicity: Excessive calcium influx dysregulates CaMKII
• Neuroprotection: CaMKII inhibition may reduce damage
• Recovery: CaMKII activity important for rehabilitation

Therapeutic Targeting

Challenges

• CNS penetration: Many inhibitors don't cross BBB
• Isoform specificity: Pan-CaMKII vs isoform-selective
• Therapeutic window: Both too much and too little are problematic

Biomarkers

Animal Models

Knockout Mice

• Camk2a null: LTP deficits, spatial memory impairment
• T286A knockin: LTP impairment, no memory consolidation

Transgenic Models

• CaMKIIa-Cre: Neuron-specific expression
• Conditional knockout: Temporal control of deletion

Disease Models

• 5xFAD mice: CaMKII deficits
• α-syn models: CaMKII activation studies
• TBI models: CaMKII in injury and recovery

Research Directions

• [Blood-brain barrier](/entities/blood-brain-barrier) penetrating CaMKII modulators
• Activity-dependent CaMKII monitoring
• Personalized medicine based on CAMK2A variants
• Combination therapies targeting multiple synaptic pathways
• Gene therapy for CAMK2A deficiency

See Also

• [CAMK2A Protein](/proteins/camk2a-protein)
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
• [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Epilepsy](/diseases/epilepsy)
• [Intellectual Disability](/diseases/intellectual-disability)
• [Autism Spectrum Disorder](/diseases/autism-spectrum-disorder)
• [Stroke](/diseases/stroke)
• [Traumatic Brain Injury](/diseases/traumatic-brain-injury)

See Also

• [CAMK2A Protein](/proteins/camk2a-protein)
• [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
• [Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
• [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Epilepsy](/diseases/epilepsy)
• [Long-Term Potentiation](/mechanisms/long-term-potentiation)

External Links

• [NCBI Gene: CAMK2A](https://www.ncbi.nlm.nih.gov/gene/815)
• [UniProt: CaMKII alpha](https://www.uniprot.org/uniprot/Q9UQF2)
• [Human Protein Atlas: CAMK2A](https://www.proteinatlas.org/ENSG00000108697-CAMK2A)

Background

References

[Lisman J, et al., The molecular basis of CaMKII function in synaptic plasticity and memory (2002)](https://pubmed.ncbi.nlm.nih.gov/11963140/)

[Soderling TR, et al., Regulation of the CaMKII and its function in synaptic plasticity (2001)](https://pubmed.ncbi.nlm.nih.gov/11399428/)

[Bayer KU, et al., Transition from Ca2+/calmodulin-dependent to Ca2+-independent CaMKII activation in neuronal plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37120651/)

[Ghosh A, et al., CaMKII dysfunction in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35181783/)

[Robison AJ, et al., CaMKII in Parkinson's disease and L-DOPA-induced dyskinesia (2021)](https://pubmed.ncbi.nlm.nih.gov/34047289/)

Pathway Diagram

The following diagram shows the key molecular relationships involving CAMK2A Gene discovered through SciDEX knowledge graph analysis: